Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Male or female ≥18 years old~* Patients with histologically confirmed solid tumors who:~  o Part 1: have tumor progression following standard therapy, have treatment-refractory disease, or for whom there is no effective standard of therapy~* Women of child-bearing potential must have a negative pregnancy test within 7 days of initiation of dosing and must agree to use an acceptable method of birth control. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥1 year. Fertile men must also agree to use an acceptable method of birth control while on study drug and up to 3 months after the last dose of study drug.~* All associated toxicity from previous or concurrent cancer therapy must be resolved (to ≤Grade 1 or Baseline) prior to study treatment administration~* Patients with stable, treated brain metastases are eligible for this trial. However, patients must not have required steroid treatment for their brain metastases within 30 days of Screening.~* Willing and able to provide written informed consent prior to any study related procedures and to comply with all study requirements~* Karnofsky performance status ≥70%~* Life expectancy ≥3 months~* Adequate hematologic, hepatic, and renal function~Exclusion Criteria~* Other than the primary malignancy, active cancer (either concurrent or within the last 3 years) that requires non-surgical therapy (e.g., chemotherapy or radiation therapy), with the exception of surgically treated basal or squamous cell carcinoma of the skin, melanoma in situ, or carcinoma in-situ of the cervix~* Chemotherapy within 28 days prior to C1D1~* Biological therapy within 5 half-lives prior to C1D1~* Radiation therapy within 28 days or 5 half-lives prior to C1D1, whichever is longer~* Investigational drug use within 28 days or 5 half-lives, whichever is longer, prior to C1D1~* Part 1 only: (a) Patients with active or a history of glucose intolerance or diabetes mellitus and (b) Hemoglobin A1c ≥7%~* ≥Grade 2 sensory neuropathy at baseline~* Uncontrolled intercurrent illness (i.e., active infection) or concurrent condition that, in the opinion of the Investigator, would interfere with the study endpoints or the patient's ability to participate~* Refractory nausea and vomiting, malabsorption, small bowel resection that, in the opinion of the Investigator, would preclude adequate absorption~* Mean QTcF ≥450 msec (for males) or ≥470 msec (for females) at Screening~* The presence of a medical or psychiatric condition that, in the opinion of the Principal Investigator, makes the patient inappropriate for inclusion in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PLX7486-TsOH, Dose escalation and RP2D (Type: EXPERIMENTAL): Part 1: Open-label, sequential PLX7486-TsOH single-agent dose escalation in approximately 60 patients with solid tumors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues